The shares are listed on the Nasdaq Global Select Market

We advised the representatives of the several underwriters in connection with the $316 million public offering by Denali Therapeutics Inc. of 11,933,962 shares (which includes the exercise in full by the underwriters of their option to purchase up to 1,556,603 additional shares). The common stock is listed on the Nasdaq Global Select Market under the symbol “DNLI.”

Based in South San Francisco, California, Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases. Denali Therapeutics pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the blood-brain barrier and guiding development with biomarker monitoring to demonstrate target engagement and select patients.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Paula Gergen and Jacquiley Wong. The intellectual property and technology transactions team included partner David R. Bauer and associate Alison T. Chin. The tax team included partner Mario J. Verdolini and associate Michelle Zhao. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post